Filters
Mechanisms of immunoresistance in glioblastoma (NS9875)
Submitted project deals with the immunosuppresive effects of glioblastoma cells caused by overexpression of transforming growth factor beta and contributes to enhancement of current cellular immunotherapy.......
FD - Onkologie a hematologie
- 2008 - 2011 •
- 9 724 tis. Kč •
- 9 724 tis. Kč •
- MZ
Řešení projektu: 1. 7. 2008 - 31. 12. 2011
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Evaluation of Cellular Immunity and Molecular Analysis of Myeloma-Specific T cells in Patients with Multiple Myeloma (NC7475)
The aim of this study is to identify and characterize myeloma-specific T cells in patients with multiple myeloma. Immunocompetent cells will be evaluated before, during and after immunotherapy in patients with multiple myeloma Differencies o...
FD - Onkologie a hematologie
- 2003 - 2005 •
- 2 498 tis. Kč •
- 2 404 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (96%)
Poskytovatel: Ministerstvo zdravotnictví
Natural Killer cell based adoptive cellular immunotherapy of hemato-oncology disorders. (NU22-08-00287)
The use of natural killer (NK) cells as a cellular immunotherapy has increased over the past decade, specifically in patients with hematologic malignancies. NK of cellular immunotherapy. In this study, we will use ...
Immunology
- 2022 - 2025 •
- 10 115 tis. Kč •
- 10 115 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2022 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
MBTA - adoptive immunotherapy of tumors (FW12010389)
The goal of the project is, through industrial research and experimental development, to develop a proven technology for the production of medicinal substances in the correct laboratory quality (SLK) for the treatment of malignant tumors, which will ...
Oncology
- 2025 - 2027 •
- 24 756 tis. Kč •
- 17 305 tis. Kč •
- TA ČR
Řešení projektu: 1. 1. 2025 - 31. 12. 2027
Uznané náklady
Podpora ze státního rozpočtu (70%)
Poskytovatel: Technologická agentura ČR
Preparation of polyclonal cancer-specific T-cells for adoptive cellular immunotherapy of prostate cancer (NV16-28135A)
Prostate cancer (PCa) accounts for the second leading cause of cancer-elicited deaths in men in Europe and the United States. The T-cell-based adoptive cellular immunotherapy (ACI) is a modern therapeutic platform increasingly used ...
EC - Imunologie
- 2016 - 2019 •
- 10 666 tis. Kč •
- 10 666 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2016 - 31. 12. 2019
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Nano-Monitoring of Cancer Immunotherapy Efficiency The Graphene Lateral Electrophoretic Bioassay platform (TH78020001)
The main goals of the program will be fulfilled by the development of a point-of-care (PoC) nanobiosensor for monitoring the effectiveness of immunotherapy of neuroblastoma with naxitamab. Naxitamab is a humanized anti-GD2 monoclonal antibod...
Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])
- 2022 - 2025 •
- 1 248 tis. Kč •
- 1 058 tis. Kč •
- TA ČR
Řešení projektu: 1. 2. 2022 - 30. 6. 2025
Uznané náklady
Podpora ze státního rozpočtu (85%)
Poskytovatel: Technologická agentura ČR
The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma (NU21-03-00539)
Cellular immunity plays a central role in the eradication of tumors, with two stimulatory and inhibitory molecules and other surface proteins within the cellular in the process of cancer immunoediting and in the response to immu...
Oncology
- 2021 - 2025 •
- 11 789 tis. Kč •
- 11 789 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2021 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
LL-37 as a novel and powerful molecular tool for boosting the performance of ex vivo-produced dendritic cells in immunotherapy of urogenital cancers (NU22-03-00300)
Cancer is the dominating cause of death, and its dominance is increasing. Immunotherapy is a dynamically developing therapeutic modality of the last few years. Active cellular immunotherapy (ACI) based on dendritic cells (D...
Immunology
- 2022 - 2025 •
- 7 718 tis. Kč •
- 7 718 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2022 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Development of experimental vaccine against WT 1 for immunotherapy of tumors (NS10660)
it was evaluated as a promising target antigen for immunotherapy of tumors. WT1 gene of combined chemo-immunotherapy of tumors comprising epigenetic sensitization of tumors to effect of antigen specific adaptive cellular i...
FD - Onkologie a hematologie
- 2009 - 2011 •
- 10 317 tis. Kč •
- 10 317 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2009 - 31. 12. 2011
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Immunotherapy of MHC class I - Tumours Modulation of the MHC Class I Expression by Demethylation, Selection of Proper Adjuvants (GA301/04/0492)
, and to develop the anti-tumour immunotherapy. We will induce the expression of the MHC class, we will investigate the capacities of peptide and cellular vaccines, when applied-step immunisation protocol leading to the immunoth...
FD - Onkologie a hematologie
- 2004 - 2006 •
- 2 979 tis. Kč •
- 2 979 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2004 - 1. 1. 2006
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
- 1 - 10 out of 1 206